April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Development of a novel multiplexed microarray lab-on-a-chip device to quantify ocular surface disease biomarkers in tears
Author Affiliations & Notes
  • Jon Careaga Goicoechea
    Biomedical R&D, Biioftalmik, Derio, Spain
  • Tatiana Maria Suarez-Cortes
    Biomedical R&D, Biioftalmik, Derio, Spain
  • Javier Soria
    Biomedical R&D, Biioftalmik, Derio, Spain
  • Arantxa Acera
    Biomedical R&D, Biioftalmik, Derio, Spain
  • Edda Reis
    Department of Nanobiotechnology & Nanomedicine, Fraunhofer Institute for Biomedical Engineering, Potsdam, Germany
  • Soeren Schumacher
    Fraunhofer ivD-platform, Fraunhofer Institute for Biomedical Engineering, Potsdam, Germany
  • Xabier Landaluce
    Biomedical R&D, Biioftalmik, Derio, Spain
  • Footnotes
    Commercial Relationships Jon Careaga Goicoechea, Bioftalmik (E); Tatiana Suarez-Cortes, Bioftalmik (E); Javier Soria, Bioftalmik (E); Arantxa Acera, Bioftalmik (E); Edda Reis, None; Soeren Schumacher, None; Xabier Landaluce, Bioftalmik (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2004. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jon Careaga Goicoechea, Tatiana Maria Suarez-Cortes, Javier Soria, Arantxa Acera, Edda Reis, Soeren Schumacher, Xabier Landaluce; Development of a novel multiplexed microarray lab-on-a-chip device to quantify ocular surface disease biomarkers in tears. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2004.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Ocular surface diseases (OSD) are the major cause of ophthalmological consultation, produce symptoms as a consequence of multiple physiological processes. Evaluation of biomarker panels involved in these biological processes might be a good strategy for diagnosis and monitoring ocular diseases. In the present study, the development of a multiplexed microarray-based device has been performed

Methods: Three previously validated biomarkers for OSD (S100A6, CST4 and MMP9) were selected for the integration into a lab-on-a-chip system (Fraunhofer ivD-platform) with capacity for 500 protein spots. The integration process consisted on several steps: i) identification of specific capture and detection antibodies for biomarkers; ii) selection of an appropriate microarray surface for antibody immobilization; iii) evaluation of cross-reactivity between antibodies; iv) determination of detection limits; v) technical validation of the platform with tear samples

Results: Critical parameters for protein quantification on Fraunhofer ivD-platform were established. Detection dynamic ranges of the selected antibody pairs fulfilled the requirements for quantification in tears into clinical relevance range. No crossreactivity was detected on the system. Technical validation with 1 µl of tear samples confirmed accuracy of previously reported data in ELISA assays

Conclusions: A novel lab-on-a-chip system was successfully developed for simultaneous quantification of three OSD biomarkers. The device fulfilled technical requirements for clinical practice use. Additional biomarkers for other OSD might further be included, making this novel lab-on-a-chip system a potential multi-disease tool for management of OSD

Keywords: 486 cornea: tears/tear film/dry eye • 467 clinical laboratory testing • 557 inflammation  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×